Unknown

Dataset Information

0

Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation.


ABSTRACT: Tolvaptan, a vasopressin type 2 receptor antagonist initially developed to increase free-water diuresis, has been approved for the treatment of autosomal dominant polycystic kidney disease in multiple countries. Furthermore, tolvaptan has been shown to improve the renal functions in rodent models of chronic kidney disease (CKD); however, the underlying molecular mechanisms remain unknown. CKD is characterized by increased levels of oxidative stress, and an antioxidant transcription factor-nuclear factor erythroid 2-related factor 2 (Nrf2)-has been gaining attention as a therapeutic target. Therefore, we investigated the effects of tolvaptan and a well-known Nrf2 activator, bardoxolone methyl (BARD) on Nrf2. To determine the role of tolvaptan, we used a renal cortical collecting duct (mpkCCD) cell line and mouse kidneys. Tolvaptan activated Nrf2 and increased mRNA and protein expression of antioxidant enzyme heme oxygenase-1 (HO-1) in mpkCCD cells and the outer medulla of mouse kidneys. In contrast to BARD, tolvaptan regulated the antioxidant systems via a unique mechanism. Tolvaptan activated the Nrf2/HO-1 antioxidant pathway through phosphorylation of protein kinase RNA-like endoplasmic reticulum kinase (PERK). As a result, tolvaptan and BARD could successfully generate synergistic activating effects on Nrf2/HO-1 antioxidant pathway, suggesting that this combination therapy can contribute to the treatment of CKD.

SUBMITTER: Fujiki T 

PROVIDER: S-EPMC6592894 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation.

Fujiki Tamami T   Ando Fumiaki F   Murakami Kana K   Isobe Kiyoshi K   Mori Takayasu T   Susa Koichiro K   Nomura Naohiro N   Sohara Eisei E   Rai Tatemitsu T   Uchida Shinichi S  

Scientific reports 20190625 1


Tolvaptan, a vasopressin type 2 receptor antagonist initially developed to increase free-water diuresis, has been approved for the treatment of autosomal dominant polycystic kidney disease in multiple countries. Furthermore, tolvaptan has been shown to improve the renal functions in rodent models of chronic kidney disease (CKD); however, the underlying molecular mechanisms remain unknown. CKD is characterized by increased levels of oxidative stress, and an antioxidant transcription factor-nuclea  ...[more]

Similar Datasets

| S-EPMC8326123 | biostudies-literature
| S-EPMC8055680 | biostudies-literature
| S-EPMC5832143 | biostudies-literature
| S-EPMC6932784 | biostudies-literature
| S-EPMC3752779 | biostudies-literature
| S-EPMC5360972 | biostudies-literature
| S-EPMC6337568 | biostudies-literature
| S-EPMC7549774 | biostudies-literature
| S-EPMC9386133 | biostudies-literature
| S-EPMC2970706 | biostudies-literature